Document Detail


The progression from hypertension to heart failure.
MedLine Citation:
PMID:  9366285     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Heart failure (HF) still presents a major health problem despite significant understanding of its underlying pathophysiology and recent therapeutic advances. Hypertension is a major risk factor for HF and plays a key role in the evolution of the disease. In an attempt to compensate for the increased peripheral resistance frequently noted in hypertension, the heart may hypertrophy, with the left ventricular enlargement accompanied by fibrosis and resulting in reduced contractility. Ultimately the hypertrophied or fibrosed myocardium is no longer able to maintain normal cardiac output and left ventricular failure occurs. Evidence shows that treating hypertension effectively can have a major beneficial impact on some, but not all, forms of adult cardiovascular disease. For example, the incidence of HF and stroke are clearly reduced; however, until recently, treating hypertension has had relatively little effect on coronary heart disease (CHD) events. The benefits of antihypertensive treatment are, however, clearly underestimated, possibly because many studies are too short and because more subtle benefits of treatment have been overlooked. Also, it must be realized that hypertension is a complex disorder and antihypertensive drugs do indeed differ regarding their effects on associated metabolic derangements often seen in hypertensive patients. Angiotensin converting enzyme (ACE) inhibitors have been shown to be highly efficacious and safe antihypertensive agents, and have additional favorable effects on metabolic parameters, renal functions, and cardiac hypertrophy. ACE inhibitors are now the mainstay of therapy in the patients with heart failure and it is now well recognized that earlier and more aggressive treatment of hypertension may reduce the incidence of HF. ACE inhibitors are an excellent choice as an antihypertensive agent; however, many physicians limit their use of ACE inhibitors due to concern about possible renal side-effects, which accompanied the early use of these agents at very high doses.
Authors:
P C Deedwania
Related Documents :
7873465 - Neurohormonal mechanisms and the role of angiotensin-converting enzyme (ace) inhibitors...
8749265 - Pathophysiological aspects of the renin-angiotensin-aldosterone system in acute myocard...
7937415 - Congestive heart failure. current and future strategies to decrease mortality.
25440505 - Bivalirudin versus heparin for percutaneous coronary intervention: an updated meta-anal...
19159405 - Activation of muscarinic receptors elicits inotropic responses in ventricular muscle fr...
18387635 - Hyperglycemia and cognitive outcome after ischemic stroke.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  American journal of hypertension     Volume:  10     ISSN:  0895-7061     ISO Abbreviation:  Am. J. Hypertens.     Publication Date:  1997 Oct 
Date Detail:
Created Date:  1997-12-09     Completed Date:  1997-12-09     Revised Date:  2009-02-24    
Medline Journal Info:
Nlm Unique ID:  8803676     Medline TA:  Am J Hypertens     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  280S-288S     Citation Subset:  IM    
Affiliation:
University of California, San Francisco, School of Medicine and VA Medical Center, Fresno 93703, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Angiotensin-Converting Enzyme Inhibitors / administration & dosage*,  adverse effects
Antihypertensive Agents / administration & dosage*
Disease Progression
Female
Fosinopril / administration & dosage
Heart Failure / pathology*
Humans
Hypertension / drug therapy*,  pathology*
Hypertrophy, Left Ventricular / pathology
Kidney / drug effects
Male
Middle Aged
Chemical
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 98048-97-6/Fosinopril

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pharmacoeconomics of angiotensin converting enzyme inhibitors in heart failure.
Next Document:  Treatment of congestive heart failure: experience with fosinopril.